Article: Randomized study of intravesical pirarubicin chemotherapy with low and intermediate-risk nonmuscle-invasive bladder cancer in Japan: Comparison of a single immediate postoperative intravesical instillation with short-term adjuvant intravesical...

Purpose: The objective of this study was to evaluate the efficacy, defined by the 3-year tumor recurrence-free survival rate, of intravesical chemotherapy using pirarubicin (THP) in patients with low or intermediate-risk nonmuscle-invasive bladder cancer (NMIBC).

Patients And Methods: Between October 2010 and January 2015, 206 patients were enrolled, and finally 113 were randomized to receive either a single immediate postoperative intravesical instillation of THP (30 mg) (Group A), or 8 additional weekly intravesical instillations of THP (30 mg) after a single postoperative instillation (Group B). The patients were examined by performing cystoscopy and urine cytology every 3 months after transurethral resection to determine bladder tumor recurrence. The primary endpoint was 3-year-recurrence-free survival rate.

Results: All 113 patients were bacillus Calmette-Guérin (BCG)-naïve. The 3-year recurrence free survival rate was 63.7% for Group A and 85.3% for Group B (log-rank test, P = .0070). In patients with intermediate recurrence risk, the 3-year recurrence-free survival rate was 63.4% in Group A and 86.1% in Group B (log-rank test, P = .0036). Cox regression analysis revealed that only additional instillation of THP was a significant independent factor for recurrence-free rate in patients with intermediate risk. No patient with progression was noted during this period. Frequent adverse effects (AEs) were frequent urination and micturition pain, and no severe AEs (Grade 3 or more) occurred.

Conclusion: Additional instillation of THP (30 mg) weekly for 8 weeks reduced the risk of tumor recurrence without severe AEs in BCG-naïve NMIBC patients with intermediate risk.

Citing Articles

A Comprehensive Review of Current Approaches in Bladder Cancer Treatment.

Kumbham S, Md Mahabubur Rahman K, Foster B, You Y ACS Pharmacol Transl Sci. 2025; 8(2):286-307.

PMID: 39974639 PMC: 11833730. DOI: 10.1021/acsptsci.4c00663.

The optimal intravesical maintenance chemotherapy scheme for the intermediate-risk group non-muscle-invasive bladder cancer.

Chen J, Huang W, Zhang Q, Deng C, Wei J, Xie Y BMC Cancer. 2023; 23(1):1018.

PMID: 37872516 PMC: 10591423. DOI: 10.1186/s12885-023-11523-9.

Guidance of adjuvant instillation in intermediate-risk non-muscle invasive bladder cancer by drug screens in patient derived organoids: a single center, open-label, phase II trial.

Seiler R, Egger M, De Menna M, Wehrli S, Minoli M, Radic M BMC Urol. 2023; 23(1):89.

PMID: 37170307 PMC: 10176900. DOI: 10.1186/s12894-023-01262-1.

Safety Assessment of Ultrasound-Assisted Intravesical Chemotherapy in Normal Dogs: A Pilot Study.

Sasaki N, Ikenaka Y, Aoshima K, Aoyagi T, Kudo N, Nakamura K Front Pharmacol. 2022; 13:837754.

PMID: 35370726 PMC: 8974685. DOI: 10.3389/fphar.2022.837754.

Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Abridged version.

Bhindi B, Kool R, Kulkarni G, Siemens D, Aprikian A, Breau R Can Urol Assoc J. 2022; 15(8):230-239.

PMID: 35099374 PMC: 8418252. DOI: 10.5489/cuaj.7487.

References

1.

Tolley D, Parmar M, Lallemand G, Benyon L, Fellows J, Freedman L . The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol. 1996; 155(4):1233-8. View

2.

Sylvester R, Oosterlinck W, Witjes J . The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur Urol. 2008; 53(4):709-19. PMC: 2587437. DOI: 10.1016/j.eururo.2008.01.015. View

3.

Koga H, Ozono S, Tsushima T, Tomita K, Horiguchi Y, Usami M . Maintenance intravesical bacillus Calmette-Guérin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group. Int J Urol. 2010; 17(9):759-66. DOI: 10.1111/j.1442-2042.2010.02584.x. View

4.

Li N, Ye Z, Na Y . Efficacy of immediate instillation combined with regular instillations of pirarubicin for Ta and T1 transitional cell bladder cancer after transurethral resection: a prospective, randomized, multicenter study. Chin Med J (Engl). 2013; 126(15):2805-9. View

5.

Babjuk M, Burger M, Capoun O, Cohen D, Comperat E, Dominguez Escrig J . European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur Urol. 2021; 81(1):75-94. DOI: 10.1016/j.eururo.2021.08.010. View

6.

Miki T, Nonomura N, Kojima Y, Okuyama A, Nakano E, Kiyohara H . [A randomized study on intravesical pirarubicin (THP) chemoprophylaxis of recurrence after transurethral resection of superficial bladder cancer]. Hinyokika Kiyo. 1998; 43(12):907-12. View

7.

Kawamura J, Tochigi H, Obata K, Ueda K, OTAGURO K, Kuriyama M . [A randomized study of pirarubicin (THP) versus adriamycin (ADM) for intravesical instillation therapy against superficial bladder cancer]. Hinyokika Kiyo. 1992; 38(3):379-85. View

8.

Sylvester R, Oosterlinck W, Holmang S, Sydes M, Birtle A, Gudjonsson S . Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial.... Eur Urol. 2015; 69(2):231-44. DOI: 10.1016/j.eururo.2015.05.050. View

9.

Huncharek M, McGarry R, Kupelnick B . Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res. 2001; 21(1B):765-9. View

10.

Okamura K, Kinukawa T, Tsumura Y, Otani T, Itoh H, Kobayashi H . A randomized study of short-versus long-term intravesical epirubicin instillation for superficial bladder cancer. Nagoya University Urological Oncology Group. Eur Urol. 1998; 33(3):285-8; discussion 289. DOI: 10.1159/000019581. View

Randomized Study of Intravesical Pirarubicin Chemotherapy with Low and Intermediate-risk Nonmuscle-invasive Bladder Cancer in Japan: Comparison of a Single Immediate Postoperative Intravesical Instillation with Short-term Adjuvant Intravesical...